Print
Email
Print Edition StoriesImmunoGen Inc. has begun clinical testing of its drug candidate SAR566658 in treating ovarian, breast, cervical, lung and pancreatic cancers.
The Cambridge biotech has worked with Paris pharmaceutical giant Sanofi-aventis to co-develop SAR566658, which uses ImmunoGen’s Targeted Antibody Payload technology. The technology has prompted a $1 million milestone payment from Sanofi-aventis, which has started clinical evaluations, to ImmunoGen (Nasdaq: IMGN).
The research collaboration between the two companies began in 2003. Sanofi-aventis is responsible for product development, clinical testing, manufacturing and marketing, while ImmunoGen retains some co-promotion rights. The Cambridge biotech also stands to receive milestone payments and royalties from sales of products related to the technology.
Read more about ImmunoGen’s SAR566658 clinical testing.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
